Brazikumab: Data from P2 EXPEDITION trial (NCT03616821) for ulcerative colitis in 2021 or later (AstraZeneca) - Jul 30, 2020 - H1 2020 Results: Data from P2 trial (NCT04277546) for ulcerative colitis in 2021 or later
P2 data • Inflammatory Bowel Disease • Ulcerative Colitis
|